Defense Partnership Army collaboration on CyPath Lung demonstrates a direct route to military healthcare channels and defense research programs. This positions bioAffinity to pursue DoD or VA adoption of noninvasive lung cancer diagnostics, with potential for funded studies and expanded procurement. Leverage this momentum by aligning business development with defense clinicians, building scalable study packages, and addressing regulatory and data sharing requirements.

Academic Hospital Outreach Engagement with premier medical centers is evident through symposium appearances and high profile Medical and Scientific Advisory Board hires. The licensing of CyPath Lung as an LDT through Precision Pathology Services suggests a scalable go to market model with specialty labs and hospital pathology networks. Focus business development on validation partnerships with cancer centers and lung screening programs to build an evidence base and expand lab distribution.

International Expansion An Australian patent application for a platform to detect and characterize multiple lung diseases signals a strategic path for international IP protection and market entry. Opportunities exist to pursue regulatory approvals and reimbursement partnerships in Australia and other regions, and to partner with local distributors or CROs to accelerate adoption of noninvasive lung diagnostics.

Platform Expansion The platform's multi disease detection capability expands opportunities beyond a single test, enabling cross sell to existing customers and lab networks. Business development strategies include pursuing adjacent indications such as pulmonary nodules, COPD and ILD, pursuing co development or multi disease panels, and communicating IP protection to reinforce defensible growth.

Lab Network Partnerships With modest current revenue and active financing discussions, there is room to scale via laboratory networks and strategic partnerships. The LDT model and advisory board strength can attract lab partners and revenue growth through volume based agreements, bundled screening programs, and collaboration deals with hospital networks and research institutions.